Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HERE'S THE ACTUAL NOTICE:
09:16 AIMM AutoImmune Inc. Common Stock 12/16/2013 100 Final Liquidating Distribution.
Transfer Books closed. ($0.023/share); Ex-Date: 12/16/2013;
so trading closed on Friday?
no more treading on this one?
,,,,,,,Means: Company liquidates and pays out divy to shareholders then closes its books for trading.
final payout of what to who?
what books closed? and closed for what reason?
good or bad?
stock going up or done?
,,,,,,,Almost Like SEAOF....final payout and books closed.
Except I believe one more payment is due.
Wonder if all the sellers realize they left money on the table.
AIMM: Final Liquidating Distribution. Transfer Books closed. ($0.023/share); Ex-Date: 12/16/2013;
http://www.otcbb.com/asp/dailylist_detail.asp?d=12/13/2013&mkt_ctg=NON-OTCBB
Nice to see you here, Taser. You done any DD on this?
Gonna be a huge day come Monday morning
17M shares O/S. Float is probably even lower. If news is coming out and this gets volume... it's going to multi-dollars.
Somebody knows something.
Wow!
Congrats AIMM
I'm not sure what is going on either but i like the fact that there are no pumpers here. Somebody is loading up big time
I'm trying to figure that out myself....if we get another post we will be on top of the breakout boards! lolzzzz
Pink No Information 7700 3mo. avg vol.
Contact Info
1199 Madia Street
Pasadena, CA 91103
Website: http://www.autoimmuneinc.com
Phone: (626) 792-1235
Update Company Info
Business Description
Financial Reporting/Disclosure
Reporting Status Alternative Reporting Standard
Deregistered a/o Mar 09, 2010
Audited Financials Not Available
Latest Report Not Available
Regulatory Agency Not Available
CIK 0000879106
Fiscal Year End 12/31
OTC Market Tier OTC Pink No Information
Profile Data
SIC - Industry Classification 2836 - Biological products, except diagnostic
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers
Robert C. Bishop CEO
Company Directors
Robert C. Bishop Chairman
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
AIMM Security Details
Share Structure
Market Value1 $20,400 a/o Sep 21, 2012
Shares Outstanding 16,999,623 a/o Mar 16, 2008
Float Not Available
Authorized Shares Not Available
Par Value 0.01
Shareholders
Shareholders of Record 200 a/o Mar 21, 2008
Corporate Actions
Ex. Date Record Date Pay Date
Dividend (0.48) Jan 10, 2011 Jun 30, 2010 Dec 30, 2010
Security Notes
Latest Addt'l Issue=8-95 3,500,000 shs at $16 by Hambrecht & Quist et al.
Short Selling Data
Short Interest 2,462 (0%)
Aug 31, 2012
Significant Failures to Deliver No
Transfer Agent(s)
Computershare Trust Company Inc.
Possible further distribution not before
2013
MK
AutoImmune Inc. Reports 2009 First Quarter Financial Results
May 7, 2009 5:04:00 PM
Email Story Discuss on ZenoBank
View Additional ProfilesPASADENA, Calif., May 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $170,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2009, compared with a net loss of $107,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2008. As of March 31, 2009, the Company reported $8.5 million in cash and marketable securities, the same amount reported as of December 31, 2008.
Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first quarter of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the fourth quarter of 2008 and from the first quarter of 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."
AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis. We expect results from the second Phase III trial should be available during the last half of 2010.
AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.
Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."
- Financial Chart Follows -
AUTOIMMUNE INC.
STATEMENT OF OPERATIONS
(Unaudited)
Three months ended
March 31,
2008 2009
---- ----
Revenue $67,000 $104,000
------- --------
Costs and expenses:
Cost of goods sold 12,000 20,000
Research and development 42,000 71,000
General and administrative 205,000 188,000
------- -------
Total costs and expenses 259,000 279,000
------- -------
Interest income 84,000 9,000
84,000 9,000
------ -----
Net loss (108,000) (166,000)
Net income (loss) attributable to
noncontrolling interest 1,000 (4,000)
----- ------
Net loss attributable to AutoImmune Inc ($107,000) ($170,000)
========= =========
Net loss per share - basic ($0.01) ($0.01)
====== ======
Net loss per share - diluted ($0.01) ($0.01)
====== ======
Weighted average common shares
outstanding - basic 16,997,205 16,999,623
========== ==========
Weighted average common shares
outstanding - diluted 16,997,205 16,999,623
========== ==========
CONDENSED BALANCE SHEET
(Unaudited)
December 31, March 31,
2008 2009
---- ----
Cash and marketable securities $8,475,000 $8,463,000
Other current assets 195,000 148,000
Total assets $8,670,000 $8,611,000
========== ==========
Current liabilities $147,000 $228,000
Total equity 8,523,000 8,383,000
--------- ---------
Total liabilities and equity $8,670,000 $8,611,000
========== ==========
SOURCE Autoimmune Inc.
----------------------------------------------
Robert C. Bishop
Ph.D.
Chairman and Chief Executive Officer of AutoImmune Inc.
+1-626-792-1235
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
25
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
AutoImmune Inc. Reports 2008 Second Quarter Financial Results
PASADENA, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX/ -- AutoImmune Inc. (OTC Pink Sheets: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008, compared with a net loss of $62,000, or break even per share basic and diluted, for the three months ended June 30, 2007. For the six months ended June 30, 2008, the net loss was $193,000, or $0.01 per share basic and diluted, compared with net loss of $54,000, or break even per share basic and diluted for the same period in 2007. As of June 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.
Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC met our expectations during the second quarter." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."
AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS sublicensed its rights in this product to Eli Lilly and Company and subsequently stated that the only results they expect to release in 2008 from an upcoming interim analysis on the first 200 patients in its pivotal phase II/III trial evaluating MBP8298 for treatment of secondary progressive multiple sclerosis will be those related to safety and/or futility. A full analysis of the trial data should be available during the second half of 2009.
AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.
Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."
- Financial Chart Follows -
AUTOIMMUNE INC.
STATEMENT OF OPERATIONS
(Unaudited)
Three months ended June 30, Six months ended June 30,
2007 2008 2007 2008
Revenue $63,000 $101,000 $160,000 $168,000
Costs and expenses:
Cost of product
revenue 2,000 16,000 11,000 28,000
Research and
development 58,000 48,000 88,000 90,000
Selling, general
and administrative 184,000 181,000 369,000 386,000
Total costs
and expenses 244,000 245,000 468,000 504,000
Interest income 113,000 60,000 223,000 144,000
Minority interest
in joint venture 6,000 (2,000) 6,000 (1,000)
Other income - - 25,000 0
119,000 58,000 254,000 143,000
Net loss ($62,000) ($86,000) ($54,000) ($193,000)
Net loss per share -
basic ($0.00) ($0.01) ($0.00) ($0.01)
Net loss per share -
diluted ($0.00) ($0.01) ($0.00) ($0.01)
Weighted average
common shares
outstanding -
basic 16,979,623 16,999,623 16,961,344 16,998,414
Weighted average
common shares
outstanding -
diluted 16,979,623 16,999,623 16,961,344 16,998,414
CONDENSED BALANCE SHEET
(Unaudited)
December 31, June 30,
2007 2008
Cash and marketable securities $8,804,000 $8,590,000
Other current assets 167,000 137,000
Total assets $8,971,000 $8,727,000
Current liabilities $128,000 $119,000
Minority interest in joint venture 11,000 19,000
Total stockholders' equity 8,832,000 8,589,000
Total liabilities and equity $8,971,000 $8,727,000
SOURCE AutoImmune Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |